StockCIK 1802768

Royalty Pharma plc (RPRX): Insider Trades and Fund Holdings

In the past 12 months, Royalty Pharma plc insiders reported 0 open-market purchases worth $0 and 5 sales worth $13.0M; 5 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months

$0Bought by insiders, 12 months

$13.0MSold by insiders, 12 months

2Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 5, 2026.

Recent RPRX insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Oct 5	Oct 5	Marshall UristEVP	EVP	▼ SELL10b5-1	4,126	57.10	$236K	All sold	Form 4 ↗
Sep 30	Sep 28	Marshall UristEVP	EVP	▼ SELL10b5-1	4,126	57.88	$239K	−50%	Form 4 ↗
Sep 24	Sep 22	Christopher HiteChair	Chair (ind.)	▼ SELL10b5-1	100,000	58.53	$5.85M	−27%	Form 4 ↗
Aug 19	Aug 18	Christopher HiteChair	Chair (ind.)	▼ SELL10b5-1	100,000	59.97	$6.00M	−21%	Form 4 ↗
Aug 17	Aug 13	Terrance P. CoyneCFO	CFO (ind.)	▼ SELL10b5-1	11,002	58.68	$646K	All sold	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

Insider	Role	Bought	Sells	Sold	Latest
Marshall Urist	EVP	$0	2	$474K	Oct 5, 2026
Christopher Hite	Chair	$0	2	$11.9M	Sep 24, 2026
Terrance P. Coyne	CFO	$0	1	$646K	Aug 17, 2026

Tracked funds that report RPRX

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

Fund	Quarter	Shares	Value	% of portfolio	Change
Renaissance Technologies	Q2 2026	1,935,800	$108.5M	0.15%	▲ +144.7%
Bridgewater Associates	Q2 2026	219,687	$12.3M	0.05%	▲ New

Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →